Mizoribine

Drug Profile

Mizoribine

Alternative Names: Bredinin; HE-69

Latest Information Update: 06 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asahi Kasei
  • Developer Asahi Kasei; Asahi Kasei Pharma Corp; Chong Kun Dang
  • Class Antirheumatics; Ribonucleosides; Small molecules
  • Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lupus nephritis; Nephrotic syndrome; Renal transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 06 Feb 2017 Mizoribine is still in phase III trials for Nephrotic syndrome (Treatment-resistant) and Lupus nephritis in China (PO)
  • 01 Nov 2014 Phase-III clinical trials in Lupus nephritis in China (PO) (NCT02256150)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top